(Q42247394)

19 October 2017

title

Hemodynamic responses to combined therapy with captopril and hydralazine in patients with severe heart failure (English)

1 reference

Cardiology and cardiovascular medicine

19 October 2017

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(83)80172-7

4 October 2023

author name string

B. M. Massie

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6345633

4 October 2023

M. Packer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6345633

4 October 2023

J. T. Hanlon

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6345633

4 October 2023

D. T. Combs

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6345633

4 October 2023

language of work or name

English

0 references

publication date

1 August 1983

1 reference

full work available at URL

19 October 2017

https://api.elsevier.com/content/article/PII:S0735109783801727?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(83)80172-7

https://api.elsevier.com/content/article/PII:S0735109783801727?httpAccept=text/plain

4 October 2023

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(83)80172-7

Journal of the American College of Cardiology

4 October 2023

published in

1 reference

19 October 2017

volume

2

1 reference

19 October 2017

issue

2

1 reference

19 October 2017

page(s)

338-344

1 reference

Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980172-7

7 January 2021

Treatment of Chronic Congestive Heart Failure with Captopril, an Oral Inhibitor of Angiotensin-Converting Enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980172-7

7 January 2021

Renin, aldosterone and cardiac decompensation: Studies with an oral converting enzyme inhibitor in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980172-7

7 January 2021

Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980172-7

7 January 2021

Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980172-7

7 January 2021

Sustained Effectiveness of Converting-Enzyme Inhibition in Patients with Severe Congestive Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980172-7

7 January 2021

Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980172-7

7 January 2021

Haemodynamic, hormonal, and electrolyte responses to captopril in resistant heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980172-7

7 January 2021

Efficacy of oral angiotensin-converting enzyme inhibition with captopril therapy in severe chronic normotensive congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980172-7

7 January 2021

Hemodynamic and radionuclide effects of acute captopril therapy for heart failure: changes in left and right ventricular volumes and function at rest and during exercise

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980172-7

7 January 2021

Oral hydralazine in chronic heart failure: sustained beneficial hemodynamic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980172-7

7 January 2021

Hemodynamic improvement after oral hydralazine in left ventricular failure: a comparison with nitroprusside infusion in 16 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980172-7

7 January 2021

Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980172-7

7 January 2021

Effect of hydralazine on renal failure in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980172-7

7 January 2021

Hemodynamic characterization of tolerance to long-term hydralazine therapy in severe chronic heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980172-7

7 January 2021

Determinants of drug response in severe chronic heart failure. 1. Activation of vasoconstrictor forces during vasodilator therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980172-7

7 January 2021

Mechanisms and implications of vasodilator tolerance in the treatment of congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980172-7

7 January 2021

A comparison of the effects of vasodilator stimuli on peripheral resistance vessels in normal subjects and in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980172-7

7 January 2021

Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980172-7

7 January 2021

Dose requirements of hydralazine in patients with severe chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980172-7

7 January 2021

Postural hypotension and tachycardia during hydralazine--isosorbide dinitrate therapy for chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980172-7

7 January 2021

Long-term vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980172-7

7 January 2021

Physiologic and pharmacologic determinants of vasodilator response: a conceptual framework for rational drug therapy for chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2883%2980172-7

7 January 2021

Identifiers

1 reference

19 October 2017

1 reference